Merck CEO indicates interest in GLP-1 combination therapies, may pursue deals

Not wanting to be left out in the cold, Merck now plans to pursue GLP-1 combination therapies amid growing excitement about the lucrative potential of a drug class that may treat a wide range of conditions.

CEO Rob Davis described the drugmaker’s interest on Wednesday at the Goldman Sachs Healthcare C-suite…
Click here to view original post